ViroMed's Plasmid DNA Facility Buy Addresses Key Potential US Regulatory Hurdle

ViroMed, which is progressing Phase III clinical trials for its gene therapy VM202 in the US, has acquired a plasmid DNA manufacturing facility in San Diego, a move that will enable the South Korean biotech to provide stable supplies of the product if approved, and addressing a major uncertainty for gene therapies seeking regulatory approval from the FDA.